Press Releases
06.22.10 sanofi-aventis and Regulus Therapeutics Form Major Strategic Alliance on microRNA Therapeutics
05.27.10 Regulus Therapeutics Receives Exclusive License for Intellectual Property to microRNA-21 for Diseases of the Heart, Liver, and Kidney
04.15.10 Regulus Therapeutics Presents New Pre-clinical Data on microRNA Therapeutics for Diabetes
03.29.10 Regulus Therapeutics and Collaborators Publish Pre-clinical In Vivo Efficacy Data on microRNA Therapeutics targeting microRNA-10b in Models of Breast Cancer Metastasis
03.17.10 Regulus Announces U.S. Allowance of Stanford Patent Application Covering miR-181a Function in Immune Cells
02.25.10 Regulus Therapeutics and GlaxoSmithKline Establish New Collaboration to Develop and Commercialize microRNA Therapeutics Targeting miR-122
01.25.10 Regulus, Alnylam and Isis Announce U.S. Allowance of Tuschl III Patent Application Covering miR-21
01.15.10 Regulus Therapeutics Present New Pre-clinical Data from Multiple Therapeutic Programs at Keystone Symposium
01.11.10 Regulus Therapeutics Appoints Zachary A. Zimmerman, Ph.D., Director of Business Development
12.17.09 Regulus Therapeutics Receives Exclusive License for Intellectual Property on Immuno-inflammatory microRNAs from the California Institute of Technology
